-
公开(公告)号：US20040086724A1
公开(公告)日：2004-05-06
申请号：US10603011
申请日：2003-06-25
发明人： Keitaro Suzuki , Yoshinari Koyama , Motoko Iijima
IPC分类号： C09D001/00
CPC分类号： B82Y30/00 , B01J13/0008 , C01P2004/03 , C01P2004/04 , C01P2004/50 , C01P2004/64 , C01P2004/82 , C01P2006/22 , C01P2006/60 , C01P2006/80 , C01P2006/82 , C09C3/06 , C09D183/04 , C09D183/14 , G02B1/105 , G02B1/14 , G02B1/16 , G02B1/18 , Y10T428/31612 , Y10T428/31663 , C08L2666/54
摘要： A stable modified metal oxide sol which contains from 2 to 50 wt %, as calculated as metal oxides, of particles (c) comprising colloidal particles (a) of a metal oxide having primary particle diameters of from 2 to 60 nm, as nuclei, and a coating material (b) consisting of colloidal particles of an acidic oxide coated on the surface of the particles (a), and which has primary particle diameters of from 2 to 100 nm.
摘要翻译： 一种稳定的改性金属氧化物溶胶，其以金属氧化物计，含有2至50重量％的包含一次粒径为2至60nm的金属氧化物的胶体颗粒（a）的颗粒（c）为核， 以及由粒子（a）表面涂覆的酸性氧化物的胶体粒子构成的涂布材料（b），其一次粒径为2〜100nm。
-
公开(公告)号：US20040018235A1
公开(公告)日：2004-01-29
申请号：US10461432
申请日：2003-06-16
发明人： Yoshio Tanizawa , Tatsuharu Shimokawa , Hirotada Ogawa , Mayumi Watanabe , Chihiro Ohashi , Hiroyuki Kawashima , Yasuo Shinoda , Toshio Inagi
IPC分类号： A61K031/366 , A61K009/22 , A61K031/225
CPC分类号： A61K31/47 , A61K9/2081 , A61K9/209 , A61K9/5026 , A61K9/5036 , A61K9/5078 , A61K9/5084
摘要： The present invention is drawn to a pharmaceutical composition characterized by containing a composition (A) which contains pitavastatin, a salt thereof, or an ester thereof and which initiates release thereof at least in the stomach, and an enteric composition (B) which contains pitavastatin, a salt thereof, or an ester thereof. By use of the controlled release pharmaceutical composition of the present invention, the blood level of pitavastatin can be maintained at an appropriate level immediately after administration over a long period of time. Thus, highly safety and effective treatment of hypercholesterolemia can be performed.
摘要翻译： 本发明涉及一种药物组合物，其特征在于含有含有匹伐他汀，其盐或其酯，至少在胃中释放的组合物（A）和含有匹伐他汀的肠溶组合物（B） ，其盐或其酯。 通过使用本发明的控释药物组合物，可以长时间给药后立即维持匹伐他汀的血药浓度。 因此，可以进行高胆固醇血症的高度安全和有效的治疗。
-
公开(公告)号：US20020111485A1
公开(公告)日：2002-08-15
申请号：US10118260
申请日：2002-04-09
发明人： Hisao Ikeda , Motohiko Hidaka , Atsumi Aoki
IPC分类号： C07D47/14
CPC分类号： C07D405/14
摘要： Optically active null-type tris-(2,3-epoxypropyl)-isocyanurate is obtained by a method of reacting isocyanuric acid with an optically active epihalohydrin, or a method of optically resolving a racemic modification of tris-(2,3-epoxypropyl)-isocyanurate by using an amylose or cellulose derivative. It is a method for producing a high melting point type tris-(2,3-epoxypropyl)-isocyanurate obtained by mixing two enantiomers of optically active null-type tris-(2,3-epoxypropyl)-isocyanurate.
-
4.发明授权公开(公告)号：US09459494B2
公开(公告)日：2016-10-04
申请号：US14038204
申请日：2013-09-26
发明人： Kimiaki Tsutsui , Takahiro Sakai , Kohei Goto
IPC分类号： G02F1/1337 , C08G73/10 , C09K19/56
CPC分类号： G02F1/133723 , C08G73/10 , C09K19/56 , Y10T428/1023
摘要： To provide a liquid crystal aligning agent useful to obtain a liquid crystal alignment film excellent in liquid crystal alignment properties, alignment controlling power and rubbing resistance, having high voltage retention characteristics and having reduced charge accumulation, and a liquid crystal display device which is less susceptible to display failure, to lowering of contrast or to image persistence.A liquid crystal aligning agent comprising a low resistance polyimide precursor having a volume resistivity of from 1×1010 to 1×1014 Ωcm when formed into a film, and a high alignment polyimide precursor or polyimide having a specific structure, and a liquid crystal display device employing this liquid crystal aligning agent.
摘要翻译： 一种液晶取向剂，其包含形成膜时体积电阻率为1×10 10〜1×10 14Ωcm的低电阻聚酰亚胺前体，具有特定结构的高取向聚酰亚胺前体或聚酰亚胺以及液晶显示装置 采用该液晶取向剂。
-
公开(公告)号：US20020095013A1
公开(公告)日：2002-07-18
申请号：US09991649
申请日：2001-11-26
IPC分类号： C08G069/00
CPC分类号： C08G73/026 , Y10T428/31551
摘要： A method of production of a homopolymer or copolymer or homo-oligomer or co-oligomer product characterised in that the product is obtained by condensation reaction of a diaminoanthracene, substituted or not, optionally with a diiminoanthracene substituted or not in the absence of anthraquinone substituted or not.
摘要翻译： 制备均聚物或共聚物或均聚低聚物或共低聚物产物的方法，其特征在于产物是通过二氨基蒽的缩合反应获得的，所述二氨基蒽被取代或未被任选取代或未被取代或不与蒽醌取代或取代的二亚氨基蒽 不。
-
公开(公告)号：US20140051857A1
公开(公告)日：2014-02-20
申请号：US14064367
申请日：2013-10-28
发明人： Shingo OWADA , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： C07D417/12 , C07D295/192 , C07D403/12 , C07D231/18 , C07D333/32
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1为键，CR10R11，氧原子，硫原子或NR12，X为OR13，SR13或NR14NR15，R2为氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫 原子或NR 23，并且R 3是该化合物或其溶剂合物的C2-14芳基，互变异构体，前药或药学上可接受的盐。
-
7.发明申请公开(公告)号：US20140023798A1
公开(公告)日：2014-01-23
申请号：US14038204
申请日：2013-09-26
发明人： Kimiaki Tsutsui , Takahiro Sakai , Kohei Goto
IPC分类号： G02F1/1337
CPC分类号： G02F1/133723 , C08G73/10 , C09K19/56 , Y10T428/1023
摘要： To provide a liquid crystal aligning agent useful to obtain a liquid crystal alignment film excellent in liquid crystal alignment properties, alignment controlling power and rubbing resistance, having high voltage retention characteristics and having reduced charge accumulation, and a liquid crystal display device which is less susceptible to display failure, to lowering of contrast or to image persistence.A liquid crystal aligning agent comprising a low resistance polyimide precursor having a volume resistivity of from 1×1010 to 1×1014 Ωcm when formed into a film, and a high alignment polyimide precursor or polyimide having a specific structure, and a liquid crystal display device employing this liquid crystal aligning agent.
摘要翻译： 提供一种液晶取向剂，其具有优异的液晶取向性，取向控制功率和耐摩擦性，具有高电压保持特性并且具有降低的电荷积聚的液晶取向膜，以及易受影响的液晶显示装置 显示失败，降低对比度或图像持久性。 一种液晶取向剂，其包含形成膜时体积电阻率为1×10 10〜1×10 14Ω·mol的低电阻聚酰亚胺前体，以及具有特定结构的高取向聚酰亚胺前体或聚酰亚胺以及液晶显示装置 采用该液晶取向剂。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.037 秒)
